Literature DB >> 10077179

Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants.

E N van Roon1, J M Verzijl, J R Juttmann, A W Lenderink, M J Blans, A C Egberts.   

Abstract

OBJECTIVE: To determine the incidence and determinants for discontinuation of initial highly active antiretroviral therapy (HAART).
DESIGN: In this retrospective follow-up study from hospital files and pharmacy dispensing data, a standard dataset was collected including patient characteristics, therapy characteristics, and HIV-monitoring parameters (e.g., CD4+ lymphocyte counts, viral load determinations). Kaplan-Meier estimates of the cumulative probability of discontinuation of initial HAART were calculated. Cox proportional hazard analysis was used to identify determinants for discontinuation of initial HAART. PATIENTS: All patients starting HAART (n = 99) during June 1996 to February 1997 at our regional AIDS center. MAIN OUTCOME MEASURES: Incidence and determinants for discontinuation of HAART.
RESULTS: During the mean follow-up of 450+/-10 days, 27 patients switched initial HAART, 3 patients stopped any antiretroviral therapy. Reasons for switching were increasing viral load (18x), insufficient decrease of viral load (3x), and adverse events (6x). Nonnaivete for antiretroviral therapy and a lower CD4+ lymphocyte count at start were identified as determinants for discontinuation of initial HAART.
CONCLUSIONS: The overall incidence density for discontinuation of initial HAART was 25 per 100 patients/year. The main reason for switching was an increasing viral load. CD4+ lymphocyte counts at start and nonnaivete for antiretroviral therapy were identified as determinants for discontinuation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10077179     DOI: 10.1097/00042560-199903010-00012

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  15 in total

Review 1.  Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature.

Authors:  Albert M L Anderson; John A Bartlett
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

Review 2.  Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.

Authors:  D P Figgitt; G L Plosker
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

3.  The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men.

Authors:  Gregory S Zaric; Ahmed M Bayoumi; Margaret L Brandeau; Douglas K Owens
Journal:  Med Decis Making       Date:  2008-03-18       Impact factor: 2.583

4.  Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada.

Authors:  H Samji; T E Taha; D Moore; A N Burchell; A Cescon; C Cooper; J M Raboud; M B Klein; M R Loutfy; N Machouf; C M Tsoukas; J S G Montaner; R S Hogg
Journal:  HIV Med       Date:  2014-09-01       Impact factor: 3.180

5.  Temporal trends in the discontinuation of first-line antiretroviral therapy.

Authors:  Alejandro Gonzalez-Serna; Keith Chan; Benita Yip; William Chau; Rachel McGovern; Hasina Samji; Viviane Dias Lima; Robert S Hogg; Richard Harrigan
Journal:  J Antimicrob Chemother       Date:  2014-04-15       Impact factor: 5.790

6.  Persisting murine cytomegalovirus can reactivate and has unique transcriptional activity in ocular tissue.

Authors:  Lisa Kercher; Bradley M Mitchell
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Cost-effectiveness of HIV screening in patients older than 55 years of age.

Authors:  Gillian D Sanders; Ahmed M Bayoumi; Mark Holodniy; Douglas K Owens
Journal:  Ann Intern Med       Date:  2008-06-17       Impact factor: 25.391

8.  Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS.

Authors:  S Crystal; U Sambamoorthi; P J Moynihan; E McSpiritt
Journal:  J Gen Intern Med       Date:  2001-12       Impact factor: 5.128

9.  Assessing the performance of a computer-based policy model of HIV and AIDS.

Authors:  Chara E Rydzak; Kara L Cotich; Paul E Sax; Heather E Hsu; Bingxia Wang; Elena Losina; Kenneth A Freedberg; Milton C Weinstein; Sue J Goldie
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

10.  Profile of darunavir in the management of treatment-experienced HIV patients.

Authors:  Cameron Wolfe; Charles Hicks
Journal:  HIV AIDS (Auckl)       Date:  2009-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.